Muscular dystrophy gene therapy - Asklepios BioPharmaceutical

Drug Profile

Muscular dystrophy gene therapy - Asklepios BioPharmaceutical

Alternative Names: Biostrophin; rAAV2.5-CMV-minidystrophin (d3990)

Latest Information Update: 19 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asklepios BioPharmaceutical
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Duchenne muscular dystrophy

Most Recent Events

  • 07 Oct 2010 Adverse events data from a phase I trial in Duchenne muscular dystrophy released by AskBio
  • 10 Oct 2006 Asklepios has entered into a cross-agreement with GSK to develop and commercialise gene therapy treatments for a variety of indications, including muscular dystrophy
  • 29 Mar 2006 Phase-I clinical trials in Duchenne muscular dystrophy in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top